Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizer Inversion: Prickly Politics For Pharma

This article was originally published in Scrip

Executive Summary

Certainly, Pfizer Inc. knew what it was doing when it decided to consider another possible merger under a tax inversion scheme in the midst of the high-stakes political battle ongoing in the US – bringing with such a move more condemnation of the entire biopharmaceutical industry, which already is under fire for certain firms' drug pricing practices and some shady looking relationships with specialty pharmacies.



Related Companies